---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-902"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-902. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 30 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-902"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-902

<a id="heading-3.1.11"></a>

## 3.1.11 ABX464-902

<a id="heading-3.1.11.1"></a>

### 3.1.11.1 Objective

<a id="topic-3.1.11.1-1"></a>

#### Primary and secondary objectives in the protocol

> “Evaluate the potential for inhibition and/or induction of CYP1A2 in vivo based on the PK of caffeine (a known CYP1A2 substrate) in the presence and absence of ABX464.”
> “Evaluate whether ABX464 is a substrate for CYP1A2 in vivo based on its PK in the presence and absence of fluvoxamine.”
> “Evaluate the safety and tolerability of ABX464 alone and in the presence of caffeine or fluvoxamine.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.1-2"></a>

#### Purpose stated in the registry record

> “A two part, fixed-sequence, open-label crossover study to evaluate potential CYP1A2-mediated drug-drug interactions of ABX464 in healthy subjects using caffeine and fluvoxamine as probe drugs”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="heading-3.1.11.2"></a>

### 3.1.11.2 Location and Study Date

<a id="topic-3.1.11.2-1"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2020-12-17” |
| Primary completion (actual) | “2021-05-18” |

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.2-2"></a>

#### Results reporting dates in the registry record

| Field | Registry entry |
| --- | --- |
| Results first submitted | “2022-05-06” |
| Results first posted | “2026-11-09” |
| Other study ID numbers | “ABX464-902” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.2-3"></a>

#### Single site in Wales, United Kingdom

> “Study recruitment for this study was undertaken in South Wales in the United Kingdom. The recruitment process began in December 2020 and concluded in April 2021.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

> “The study will be conducted in 60 healthy volunteers (males and females) at Simbec-Orion Clinical Pharmacology Unit in Merthyr Tydfil, South Wales.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.3"></a>

### 3.1.11.3 Study Design

<a id="topic-3.1.11.3-1"></a>

#### Phase 1, two-part, fixed-sequence, open-label crossover design

> “This is a Phase 1, 2 part, fixed-sequence open-label, crossover study to evaluate the potential CYP1A2-mediated drug-drug interactions (DDI), safety, and tolerability of ABX464 combined with a known CYP1A2 substrate (caffeine) and a known CYP1A2 inhibitor (fluvoxamine).”
> “Separate cohorts of subjects will be enrolled for Part A (up to 24 subjects enrolled to allow 22 subjects required to complete Part A ) and Part B (up to 36 subjects enrolled to allow 32 subjects were to complete Part B).”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.3-2"></a>

#### Perpetrator and victim roles in each part

> “In Part A of the study ABX464 is considered the ‘perpetrator’ drug and caffeine the ‘victim’ drug.”
> “In Part B of the study ABX464 is considered the victim drug and fluvoxamine the perpetrator drug.”
> “The co-administration on Day 4 is to evaluate the potential for inhibition of CYP1A2 by the perpetrator drug (ABX464) following a single dose, while the co-administration on Day 17 is to evaluate the potential for induction of CYP1A2 by the perpetrator following multiple dosing for 14 days”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.3-3"></a>

#### Rationale for the open-label design

> “As the PK parameters investigated are objective, it was considered that there was only minimal risk of introducing bias into the study.”
> “The crossover design permits within-subject comparison, which results in reduced variability of the data obtained.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.4"></a>

### 3.1.11.4 Eligibility Criteria

<a id="topic-3.1.11.4-1"></a>

#### Key inclusion and exclusion criteria in the registry record

> “Healthy, male or female subject, between 18 and 55 years of age, inclusive.”
> “Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, or any product known to interact with CYP1A2 within 28 days or 5 half-lives (whichever is longer) prior to the first dose of IMP.”
> “Users of nicotine products i.e., current smokers or ex-smokers who have smoked within 6 months prior to first dose administration with the study medication or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums).”
> “Experiences regular headaches (i.e., experiences headaches more than weekly).”
> “Clinically significant history of depression or anxiety.”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="heading-3.1.11.5"></a>

### 3.1.11.5 Treatment

<a id="topic-3.1.11.5-1"></a>

#### Part A: caffeine with and without obefazimod

> “Using a fixed-sequence crossover study design, the Pharmacokinetics (PK) of caffeine (50 milligrams (mg) single oral dose) will be evaluated in the absence and presence of ABX464 (50 mg once daily for 14 days). Caffeine will be administered on Day 1 in the absence of ABX464, on Day 4 simultaneously with ABX464 to evaluate potential CYP1A2 inhibition by ABX464, and on Day 17 simultaneously with ABX464 following 14 days of once daily dosing of ABX464 to evaluate potential CYP1A2 induction by ABX464.”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.5-2"></a>

#### Part B: obefazimod with and without fluvoxamine

> “Using a fixed-sequence crossover study design, the PK of ABX464 (50 mg single oral dose) will be evaluated in the absence and presence of fluvoxamine (100 mg once daily for 10 days). ABX464 will be administered on Day 1 in the absence of fluvoxamine and on Day 11 simultaneously with fluvoxamine following 10 days of once daily dosing of fluvoxamine to evaluate whether ABX464 is a substrate for CYP1A2”

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.5-3"></a>

#### Dose selection and administration with food

> “The dose of 50 mg ABX464 was chosen as this is anticipated as the recommended clinical dose during subsequent clinical trials. In addition, given the established significant effect of food on the PK of ABX464, all doses of ABX464 will be administered within 30 minutes (mins) of the consumption of a standardised breakfast.”
> “Fluvoxamine: 100 mg once daily for 10 days followed by tapering period of 50 mg for 7 days then 25 mg for 7 days.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.6"></a>

### 3.1.11.6 Study Outcomes

<a id="heading-3.1.11.6.1"></a>

#### 3.1.11.6.1 Rationale for Using Caffeine and Obefazimod Cmax and AUC as the Primary Endpoints

<a id="topic-3.1.11.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Part A - Day 1 Peak Plasma Concentration of Caffeine” | “Day 1” |
| Primary | “Part A - Day 17 AUC of Caffeine & ABX464” | “Day 17” |
| Primary | “Part B - Day 1 - Peak Plasma Concentration of ABX464” | “Day 1” |
| Primary | “Part B - Day 11 - Area Under the Plasma Concentration Versus Time Curve (AUC)” | “Day 11” |
| Secondary | “Number of Adverse Events (AEs)” | “From baseline up to Day 25” |

Source: [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.6.1-2"></a>

##### In vitro basis for a CYP1A2 interaction study

> “Oxidative metabolism via the cytochrome (CYP) P450 pathway was also identified as a route of metabolism for ABX464, with cytochrome P450 1A2 (CYP1A2) identified as the major contributing isoform. Subsequent studies also demonstrated that ABX464 was a strong inhibitor of CYP1A2 in human liver microsomes and induced its expression in human hepatocytes.”
> “These findings indicate a potential clinically significant interaction with co-administered CYP1A2 substrates and are the basis for this clinical study to evaluate potential CYP1A2-mediated drug interactions.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.6.1-3"></a>

##### Choice of caffeine and fluvoxamine as probe drugs

> “Caffeine was chosen as the probe victim drug for Part A as it is a well-established substrate for CYP1A2, and therefore its PK are sensitive to either inhibition or induction of CYP1A2 by a perpetrator drug.”
> “Fluvoxamine was chosen as the probe perpetrator drug for Part B as it is a well-established inhibitor of CYP1A2”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.7"></a>

### 3.1.11.7 Statistical Analysis Description

<a id="heading-3.1.11.7.1"></a>

#### 3.1.11.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.11.7.1-1"></a>

##### Sample size calculation in the protocol

> “a sample size of 22 subjects is considered sufficient to detect a 20% treatment difference with a power of 80% and alpha of 5%, based upon a geometric mean ratio of 1. To allow for a higher CV%, dropouts or subjects who otherwise fail to complete the study, 24 subjects will be enrolled in Part A of the study.”
> “a sample size of 32 subjects is considered sufficient to detect a 20% treatment difference with a power of 80% and alpha of 5%, based upon a geometric mean ratio of 1. To allow for a higher CV%, dropouts or subjects who otherwise fail to complete the study, 36 subjects will be enrolled in Part B of the study.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.7.1-2"></a>

##### Participants screened, enrolled, and analyzed

> “164 volunteers were screened for 59 eligible participants enrolled.”
> “Total number of Part A and Part B is 59 (24 and 35 respectively).”
> “Of the 24 participants enrolled into Part A of the study, 2 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for non-adherence with pre-dose caffeine restrictions.”
> “Of the 35 participants enrolled into Part B of the study, 9 participants were excluded from the PK analysis set due to meeting PK exclusion set criteria for a vomiting episode within 2 x median Tmax on either Day 1 or Day 11 and 1 participant was excluded as an early withdrawal from the study”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.7.2"></a>

#### 3.1.11.7.2 Description of Analysis Sets

<a id="topic-3.1.11.7.2-1"></a>

##### Safety and pharmacokinetic sets in the protocol

> “Safety Set: All enrolled subjects who receive at least 1 dose of IMP/NIMP will be included in the safety analysis.”
> “PK Set: Subjects will be included in the PK Set where they have received all doses of IMP/NIMP up to and including Day 17 for Part A and Day 11 for Part B and comply with the following criteria:”
> “Do not have an occurrence of vomiting (that occurs at or before 2 times median time to maximum observation concentration (Cmax; Tmax) of the appropriate treatment) or diarrhoea which renders the concentration profile unreliable;”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="topic-3.1.11.7.2-2"></a>

##### Planned statistical comparison

> “The primary pharmacokinetic endpoints of AUC0-inf, AUC0-t and Cmax will be log-transformed and analysed using an analysis of variance (ANOVA) model including fixed effects for treatment and subject.”
> “These estimates will then be back-transformed to provide estimates of the ratios of the geometric LSMeans and corresponding 90% confidence intervals.”

Source: [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf)

<a id="heading-3.1.11.8"></a>

### 3.1.11.8 Results

<a id="heading-3.1.11.8.1"></a>

#### 3.1.11.8.1 Participant Disposition

<a id="topic-3.1.11.8.1-1"></a>

##### Participant flow in the registry results

| Milestone | Part A | Part B |
| --- | --- | --- |
| Started | “24” | “35” |
| Completed | “24” | “34” |
| Withdrawal by subject | “0” | “1” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.8.2"></a>

#### 3.1.11.8.2 Baseline Characteristics

<a id="topic-3.1.11.8.2-1"></a>

##### Age and sex by study part

| Characteristic | Part A (24 participants) | Part B (35 participants) |
| --- | --- | --- |
| Age, mean (standard deviation), years | “33.7(9.44)” | “36.8(9.75)” |
| Sex, participants | “Part A Number Analyzed 24 participants Female 5 Male 19” | “Part B Number Analyzed 35 participants Female 13 Male 22” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.2-2"></a>

##### Race and ethnicity not collected

> “Race and Ethnicity were not collected from any participant.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="heading-3.1.11.8.3"></a>

#### 3.1.11.8.3 Efficacy Results

<a id="topic-3.1.11.8.3-1"></a>

##### Part A: caffeine exposure with and without obefazimod (PK analysis set, 22 participants)

| Measure, mean (standard deviation) | Day 1, caffeine alone | Day 4, caffeine and ABX464 | Day 17, caffeine and ABX464 |
| --- | --- | --- | --- |
| Caffeine Cmax, ng/mL | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL | “7420(4760)” | “5460(2740)” | “1560(719)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.3-2"></a>

##### Part B: obefazimod exposure with and without fluvoxamine (PK analysis set, 25 participants)

| Measure, mean (standard deviation) | Day 1, ABX464 alone | Day 11, ABX464 and fluvoxamine |
| --- | --- | --- |
| ABX464 Cmax, ng/mL | “23.2(12.5)” | “33.4(19.0)” |
| ABX464 AUC, h*ng/mL | “55.2(25.7)” | “73.0(34.2)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.3-3"></a>

##### Plain-language summary of the interaction results

> “ABX464 does not demonstrate any drug-drug interactions for drugs which are broken down (metabolised) by the enzyme CYP1A2 as the levels of caffeine and fluvoxamine in the blood remained similar in both the presence and absence of ABX464.”
> “ABX464 may be metabolised in the same pathway as fluvoxamine, as the levels of ABX464 in the blood showed increases in the presence of fluvoxamine.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.8.4"></a>

#### 3.1.11.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.11.8.5"></a>

#### 3.1.11.8.5 Safety Results

<a id="topic-3.1.11.8.5-1"></a>

##### Adverse events, serious adverse events, and deaths

| Measure | Part A overall | Part B overall |
| --- | --- | --- |
| Participants with any other (nonserious) adverse event | “16/24 (66.67%)” | “30/35 (85.71%)” |
| Participants with a serious adverse event | “0/24 (0.00%)” | “0/35 (0.00%)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.5-2"></a>

##### Most frequent adverse events by study part

| Adverse event | Part A overall | Part B overall |
| --- | --- | --- |
| Headache | “13/24 (54.17%)” | “25/35 (71.43%)” |
| Nausea | “7/24 (29.17%)” | “20/35 (57.14%)” |
| Vomiting | “2/24 (8.33%)” | “11/35 (31.43%)” |
| Decreased appetite | “1/24 (4.17%)” | “15/35 (42.86%)” |
| Fatigue | “3/24 (12.50%)” | “14/35 (40.00%)” |

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

<a id="topic-3.1.11.8.5-3"></a>

##### Plain-language safety summary

> “With respect to the safety objectives of the study, it was determined ABX464 was considered to be safe and well tolerated at a 50 mg dose strength, both in the presence and absence of caffeine and fluvoxamine respectively. All adverse events (side effects) which were reported were considered to be mild to moderate in severity and resolved before the study completed.”

Source: [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers)

<a id="heading-3.1.11.9"></a>

### 3.1.11.9 Study Limitations

<a id="topic-3.1.11.9-1"></a>

#### Summary

ABX464-902 enrolled 59 healthy adults in the United Kingdom (24 in Part A and 35 in Part B) and has no peer-reviewed publication. The registry results, first submitted in May 2022 and posted in November 2026, give means and standard deviations only. The protocol specified geometric least squares mean ratios with 90% confidence intervals, and neither the registry nor any other public source reports them. In Part A, the posted mean caffeine AUC was 7420 h*ng/mL on Day 1 alone and 1560 h*ng/mL on Day 17 after 14 days of obefazimod, and mean Cmax was 931 and 564 ng/mL; the HRA plain-language summary states that caffeine levels “remained similar in both the presence and absence of ABX464”, and the registry gives no analysis that reconciles the two. In Part B, mean obefazimod Cmax and AUC were higher with fluvoxamine (33.4 against 23.2 ng/mL and 73.0 against 55.2 h*ng/mL), and the HRA summary states that obefazimod “may be metabolised in the same pathway as fluvoxamine”. Nine of 35 Part B participants were excluded from the pharmacokinetic analysis for vomiting and one for early withdrawal; the registry states that these exclusions “did not impact on the overall evaluation of the study objectives”. No metabolite (ABX464-N-glucuronide) result is posted, Part B used single 50 mg doses of obefazimod, and race and ethnicity were not collected.

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results); [Abivax ABX464-902 protocol and statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/14/NCT05121714/Prot_SAP_000.pdf); [Health Research Authority research summary, ABX464 drug-drug interaction study](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/a-2-part-drug-drug-interaction-study-of-abx464-in-healthy-volunteers); [ClinicalTrials.gov NCT05121714](https://clinicaltrials.gov/study/NCT05121714)

<a id="topic-3.1.11.9-2"></a>

#### Limitations and caveats stated in the registry results

> “N/A - although a number of participants were excluded from the PK analysis sets, this did not impact on the overall evaluation of the study objectives.”

Source: [ClinicalTrials.gov NCT05121714 results](https://clinicaltrials.gov/study/NCT05121714?tab=results)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
